144873-99-4

Usage

Uses

Used in Pharmaceutical Synthesis:
(6-Bromo-pyridin-3-yl)-acetonitrile is utilized as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block for the development of new drugs and medicinal agents. (6-BROMO-PYRIDIN-3-YL)-ACETONITRILE's versatility in chemical reactions allows for the creation of a wide range of therapeutically relevant molecules, contributing to the advancement of pharmaceutical research and drug discovery.

InChI:InChI=1/C7H5BrN2/c8-7-2-1-6(3-4-9)5-10-7/h1-2,5H,3H2

Upstream product

• 101990-45-8 2-bromo-5-bromomethylpyridine 
• 143-33-9 sodium cyanide 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 151-50-8 potassium cyanide 
• 773837-37-9 sodium cyanide 
• 843646-70-8 (6-bromopyridin-3-yl)methyl methanesulfonate 
• 7677-24-9 trimethylsilyl cyanide 
• 168173-56-6 2-bromo-5-pyridylmethyl chloride 
• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 

Downstream Products

• 404361-76-8 2-(6-bromopyridin-3-yl)acetic acid 
• 928260-43-9 5-{5-[2-(tert-butoxycarbonyl-phenethyl-amino)-ethyl]-pyridin-2-yl}-thiophene-2-carboxylic acid ethyl ester 
• 936476-86-7 5-{5-[2-(tert-butoxycarbonyl-phenethyl-amino)-ethyl]-pyridin-2-yl}-thiophene-2-carboxylic acid 
• 928260-41-7 5-{5-[2-(benzyl-tert-butoxycarbonyl-amino)-ethyl]-pyridin-2-yl}-thiophene-2-carboxylic acid ethyl ester 
• 936476-75-4 5-{5-[2-(benzyl-tert-butoxycarbonyl-amino)-ethyl]-pyridin-2-yl}-thiophene-2-carboxylic acid 
• 936475-42-2 5-[5-(2-phenethylamino-ethyl)-pyridin-2-yl]-thiophene-2-carboxylic acid ethyl ester 
• 936475-44-4 5-[5-(2-benzylamino-ethyl)-pyridin-2-yl]-thiophene-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof

The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxamides as described herein, useful as histone demethyiase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

NITROGEN-CONTAINING HETEROCYCLIC ALKENYL COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL AND ORGANIC SEMICONDUCTOR DEVICE

PROBLEM TO BE SOLVED: To provide a compound that is high in charge transfer and atmosphere stability and is suitable for an organic semiconductor material, provide an organic semiconductor material comprising the compound, and provide an organic semiconductor element comprising the organic semiconductor material. SOLUTION: The present invention provides a compound represented by formula (1), specifically a compound represented by formula (2) (Ar1 is an unsaturated cyclic hydrocarbon group or the like; Ar2 is an unsaturated heterocyclic group containing nitrogen with an unshared electron pair, or the like; B is -CH=CH- or -C≡C-; X11-X13 independently represent C-R or N; at least one of X12 and X13 is N). SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2018,JPOandINPIT

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES

The object of the invention is to provide new compounds which can be used for the treatment of diseases, in particular cardiovascular and haematological diseases. The present invention describes compounds which act as specific HIF-prolyl-4-hydroxylase inhibitors and which, because of this specific in vivo action mechanism, induce HIF target genes, such as erythropoietin, and the thus produced biological processes, such as erythropoiesis, after parenteral or oral administration. The present invention relates to compounds having the general formula (I), in which A stands for CH or N, R1 stands for a substituent selected from the group formed by (C1-C6)-alkyl, trifluoromethyl, halogen, cyano, nitro, hydroxy, (C1-C6)-alkoxy, amino, (C1-C6)-alkoxycarbonyl, hydroxycarbonyl and C(=O)-NH-R4; R2 stands for a substituent selected from the group formed by halogen, cyano, nitro, (C1-C6)-alkyl, trifluoromethyl, hydroxy, (C1-C6)-alkoxy, trifluoromethoxy, amino, hydroxycarbonyl and C(=O)-NH-R8; m equals 0, 1 or 2; n equals 0, 1, 2 or 3, it being possible for these meanings to be the same or different when R1 or R2 occurs multiple times; and R3 stands for hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl. The invention also relates to the salts, solvates, and salt solvates of these compounds.

NOVEL INDAZOLE DERIVATIVE

An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.

SUBSTITUTED INDOLE COMPOUND

Disclosed is an excellent LXR modulator. A compound represented by the general formula (I): (I) wherein R1, R2, R3 and R4: H, an alkyl which may be substituted, OH, an alkoxy which may be substituted, an amino which may be substituted, a halogeno, a phenyl or the like; R5: H or an alkyl; R6: -COR8 (wherein R8: an alkoxy which may be substituted, a phenyloxy which may be substituted, an amino which may be substituted, or the like), -SO2R9 (wherein R9: an alkyl which may be substituted, a phenyl which may be substituted or a heterocyclyl which may be substituted), or an alkyl which may be substituted; R7: -X2R10 [wherein R10: -COR11 (where R11: OH, an alkoxy which may be substituted or an amino which may be substituted), -SO2R12 (where R12: an alkyl which may be substituted or amino which may be substituted), -N(R13)COR14 (where R13: H or an alkyl which may be substituted; R14: H or an alkyl which may be substituted), -N(R13)SO2R15 (where R13: as defined above; R15: an alkyl which may be substituted) or tetrazol-5-yl; and X2: a single bond or an alkylene which may be substituted]; X1: a methylene which may be substituted; Y1: a phenyl which may be substituted or a heterocyclyl which may be substituted; and Y2: an aryl which may be substituted, a heterocyclyl which may be substituted or the like], or the like.